All In Biotech

Free tool

FAERS Monitor: Stiolto Respimat

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 206756 or its brand name (Stiolto Respimat, Olodaterol Hydrochloride, Tiotropium Bromide). Reports on generic versions are filed under their own applications.

Reports

5,135

Serious

1,966

38% of reports

Hospitalization

1,071

Death reported

373

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • dyspnoea934
  • cough422
  • drug ineffective345
  • off label use304
  • fatigue254
  • headache245
  • death230
  • diarrhoea219
  • pneumonia218
  • chronic obstructive pulmonary disease207
  • nausea193
  • dizziness192
  • product quality issue170
  • asthenia140
  • fall137

Reports by year received

View as table
YearReports
20141
2015185
2016423
2017539
2018479
2019428
2020480
2021434
2022424
2023408
2024444
2025473
2026417

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,049,024 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
chronic obstructive pulmonary diseaseSignal20716.314.32,955
dyspnoeaSignal9346.86.44,704
coughSignal4226.25.61,845
product quality issueSignal1705.14.4564
pneumoniaSignal2182.82.4246
fall1371.71.438
headache2451.61.456
dizziness1921.61.441
asthenia1401.51.325
off label use3041.41.339
diarrhoea2191.41.224
fatigue2541.31.222
death2301.11.02
drug ineffective3451.11.02
nausea1931.00.90

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.